Advertisement

The FDA recently cleared a new indication for the use of implantable Beacon® electromagnetic transponders with the Calypso System in external beam radiation therapy for prostatectomy patients. Known as GPS for the Body®, the Calypso System utilizes transponders to setup and continuously track the position of targeted tissue during radiation treatment. In the event that the tumor site moves outside of acceptable limits, the clinician adapts therapy during daily treatment to ensure the treatment is delivered as prescribed to the cancerous tissue while avoiding adjacent healthy organs. This is the only technology platform designed to provide objective, accurate and continuous tracking information during external beam radiation therapy without adding ionizing radiation.
Advertisement
Advertisement